Literature DB >> 25223269

Comparison of the protective effects of killed Burkholderia pseudomallei and CpG oligodeoxynucleotide against live challenge.

Apichaya Puangpetch1, Robert Anderson2, Yan Y Huang2, Rojana Saengsot1, Rasana W Sermswan3, Surasakdi Wongratanacheewin4.   

Abstract

Melioidosis is a fatal disease caused by Burkholderia pseudomallei. Currently there is no vaccine available. Synthetic oligodeoxynucleotides with unmethylated CpG dinucleotide motifs (CpG ODN) can stimulate vertebrate immune cells and clear certain pathogens that are susceptible to a strong Th1 response. In our previous study, pretreatment with CpG ODN alone or CpG-ODN with cationic liposomes for 2-10 or 30 days before B. pseudomallei infection in mice conferred 80-100% protection. In the present study we investigated the protective effect of CpG-ODN together with heat-killed (HK) or paraformaldehyde-killed B. pseudomallei (PP). HK or PP were used to immunize BALB/c mice twice at 15-day intervals before intra-peritoneal challenge with 5LD50 of B. pseudomallei and observed for 30 days. We found that PP could significantly protect mice (60%) with an increased survival time (24.8±11.63 days) while in the HK and PBS groups, all infected mice died within 6 days. Although either CpG ODN or PP conferred significant protection, giving them in combination did not enhance it further. Serum IFN-γ levels on day-5 (before challenge) of the PP and PP+CpG ODN groups were significantly higher than those of the PBS control group. The results further support the importance of IFN-γ in host protection against B. pseudomallei and suggest further study on paraformaldehyde-killed bacteria as a component of a future B. pseudomallei vaccine.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Burkholderia pseudomallei; CpG oligodeoxynucleotide; Heat-killed Burkholderia pseudomallei; Paraformaldehyde-killed Burkholderia pseudomallei

Mesh:

Substances:

Year:  2014        PMID: 25223269     DOI: 10.1016/j.vaccine.2014.08.035

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  7 in total

1.  Recent Advances in Burkholderia mallei and B. pseudomallei Research.

Authors:  Christopher L Hatcher; Laura A Muruato; Alfredo G Torres
Journal:  Curr Trop Med Rep       Date:  2015-06

Review 2.  Human Melioidosis.

Authors:  I Gassiep; M Armstrong; R Norton
Journal:  Clin Microbiol Rev       Date:  2020-03-11       Impact factor: 26.132

Review 3.  Emerging role of biologics for the treatment of melioidosis and glanders.

Authors:  Daniel Tapia; Javier I Sanchez-Villamil; Alfredo G Torres
Journal:  Expert Opin Biol Ther       Date:  2019-10-15       Impact factor: 4.388

4.  A VLP-based vaccine provides complete protection against Nipah virus challenge following multiple-dose or single-dose vaccination schedules in a hamster model.

Authors:  Pramila Walpita; Yu Cong; Peter B Jahrling; Oscar Rojas; Elena Postnikova; Shuiqing Yu; Lisa Johns; Michael R Holbrook
Journal:  NPJ Vaccines       Date:  2017-08-08       Impact factor: 7.344

Review 5.  Current Advances in Burkholderia Vaccines Development.

Authors:  Guanbo Wang; Paulina Zarodkiewicz; Miguel A Valvano
Journal:  Cells       Date:  2020-12-11       Impact factor: 6.600

6.  Evaluation of two different vaccine platforms for immunization against melioidosis and glanders.

Authors:  Sergei S Biryukov; Christopher K Cote; Christopher P Klimko; Jennifer L Dankmeyer; Nathaniel O Rill; Jennifer L Shoe; Melissa Hunter; Zain Shamsuddin; Ivan Velez; Zander M Hedrick; Raysa Rosario-Acevedo; Yuli Talyansky; Lindsey K Schmidt; Caitlyn E Orne; David P Fetterer; Mary N Burtnick; Paul J Brett; Susan L Welkos; David DeShazer
Journal:  Front Microbiol       Date:  2022-08-17       Impact factor: 6.064

7.  Vaccines for the Prevention of Melioidosis and Glanders.

Authors:  Monica M Johnson; Kristy M Ainslie
Journal:  Curr Trop Med Rep       Date:  2017-07-14
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.